Clinical trials: Movement Abnormalities
Progressive Supranuclear Palsy
Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy
The purpose of this study is to determine wether NP031112 is safe and effective in the treatment of mild to moderate Progressive Supranuclear Palsy
- Trial name
- Tauros (NCT01049399)
- Testing
- tideglusib
- Where
- 24 sites in United States, Germany and 2 more
- Volunteers
- 146 people
- Sponsor
- Noscira SA
Parkinson's Disease
SEDPARK1: Safety and Efficacy Study With the Non-ergot Dopamine-agonist Piribedil in Parkinson's Disease
The aim of the non-interventional Post Marketing Study is to investigate the use of the non-ergot dopamine agonist piribedil (trade name: CLARIUM) in mono- and combination therapy in patients with Morbus Parkinson.
- Trial name
- PIR-001/K (NCT00725478)
- Testing
- Piribedil
- Volunteers
- 250 people
- Sponsor
- Desitin Arzneimittel GmbH
Tourette Syndrome
Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome
Phase 2, open-label, fixed-dose titration study to evaluate the safety and tolerability of NBI-98854 administered once daily for a total of 24 weeks in children, adolescents, and adults with Tourette Syndrome (TS).
- Trial name
- NCT02879578
- Testing
- Valbenazine
- Where
- 13 sites in United States
- Volunteers
- 155 people
- Sponsor
- Neurocrine Biosciences
Wilson Disease
Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial
The aim of this study is to inform and improve future clinical trials in Wilson Disease (WD) by better understanding how patients with WD are living with and managing the disease, and by identifying key factors that shape their…
- Trial name
- NCT07226622
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Prime Medicine, Inc.
Parkinson's Disease (PD)
Health Related Quality of Life in LCIG Patients and LCIG Eligible Patients Continuing Oral Therapy
The aim of this study is to assess the effect of LCIG (levodopa-carbidopa intestinal gel) on HRQL (Health-Related Quality of Life) of participants and compare the Health-Related Quality of Life between participants continuing to…
- Trial name
- BALANCE (NCT02381444)
- Where
- 27 sites in Germany, Switzerland
- Volunteers
- 136 people
- Sponsor
- AbbVie
Huntington Disease
Mass Balance Study of [14C] LPM3770164 in Healthy Participants
This is a phase 1, single-center, single-dose, open-label mass-balance study to evaluate radioactive recovery rate, radioactive PK characteristics, metabolite identification, and to observe the safety in healthy male subjects of…
- Trial name
- NCT07516899
- Testing
- [14C] LPM3770164
- Where
- China
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Tardive Dyskinesia
Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia
The purpose of this study is to assess the safety and efficacy of three doses (12.5, 25, and 50 mg) of NBI-98854 for the treatment of the symptoms of tardive dyskinesia (TD) in subjects with schizophrenia or schizoaffective…
- Trial name
- NCT01267188
- Testing
- NBI-98854
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Neurocrine Biosciences
Huntington Disease, Tardive Dyskinesia
Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets
This is a A single-center, randomized, open-label, two-dose, two-period, crossover trial was conducted to evaluate the effect of food on the Pharmacokinetic characteristics and safety of oral administration of LPM3770164…
- Trial name
- NCT06474650
- Testing
- LPM3770164 sustained release tablet
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Parkinson's Disease, Restless Leg Syndrome
A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted Conditions
The objective of this study was to assess the single dose bioequivalence of Roxane's Ropinirole Tablets, 0.25 mg to ReQuip Tablets, 0.25 mg (GlaxoSmithKline) under fasting conditions using a single-dose, randomized, 2-treatment…
- Trial name
- NCT00673088
- Testing
- Ropinirole Hydrochloride
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Huntington Disease, Huntington's Dementia
Prospective Single-Timepoint Huntington's Disease Biospecimen Collection Study
OBJECTIVES: The primary study objective is to collect blood from participants with Huntington's Disease in order to validate a CE marked Cytosine, Adenine, Guanine (CAG) assay for use in future studies for Huntington's Disease.
- Conditions
- Huntington Disease, Huntington's Dementia, Huntington Disease, Late Onset, Huntington; Dementia (Etiology)
- Trial name
- SAN-09611 (NCT05773196)
- Testing
- Biospecimen Collection
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Sanguine Biosciences
Parkinson Disease, Gait Disorders, Neurologic
Automated Mechanical Peripheral Stimulation to Treat Freezing of Gait in Patients With Parkinson's Disease and STN-DBS
The objective is to investigate whether AMPS (Automated Mechanical Peripheral Stimulation) is effective in reduction of FOG measured via the FOG-AC (Freezing Of Gait Assessment Course) in people with Parkinson Disease and STN-DBS…
- Trial name
- AMBITION (NCT04831879)
- Testing
- GONDOLA AMPS
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Gondola Medical Technologies SA
Cardiac Disease, Respiratory Disease
Clinical Use Cases Assessment of the Gabi System in Young Children With Underlying Medical Conditions (BRIDGE Study)
Subjects will use the Gabi system on a daily basis for 3 months, each time the subject is resting or asleep. The Gabi system will recording the SpO2, pulse rate, respiratory rate and movements of the subject.
- Conditions
- Cardiac Disease, Respiratory Disease, Congenital Cardiac Defect, Cardiovascular Diseases
- Trial name
- BRIDGE (NCT05319236)
- Testing
- Gabi System
- Where
- 4 sites in United States, Belgium
- Volunteers
- 101 people
- Sponsor
- Gabi SmartCare
Alzheimer's Disease, Huntington's Disease
A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users
Dimebon will not exhibit abuse potential when compared to placebo or a positive control (alprazolam).
- Trial name
- NCT00975481
- Testing
- dimebon, alprazolam
- Volunteers
- 36 people
- Sponsor
- Pfizer
Movement Disorders and Physical Impairments
Assessing the Colgate Assist Handle Toothbrush in Individuals With Impairment of Hand Movement.
User experiences of Colgate Assist Handle toothbrush as indicated by questionnaire and interview
- Trial name
- NCT06632704
- Testing
- Colgate Toothbrush assist
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Colgate Palmolive
Huntington's Disease
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease
This is a first-in-human (FIH) study of RG6496 that will assess the safety and tolerability of single-ascending doses of RG6496 administered to huntington's disease gene expansion carriers (HDGECs).
- Trial name
- POINT-HD (NCT07246941)
- Testing
- RG6496
- Where
- 7 sites in Argentina, Australia and 3 more
- Volunteers
- 3 people
- Sponsor
- Hoffmann-La Roche
Parkinson's Disease
Pharmacokinetic Study in Healthy Males
The purpose of this study is to investigate the pharmacokinetics of levodopa, carbidopa, 3-OMD and ODM-104 after repeated doses of 3 levodopa formulations given in combination with carbidopa and ODM-104.
- Trial name
- NOCOF (NCT02312232)
- Testing
- levodopa, carbidopa, ODM-104
- Where
- Finland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma
Parkinson Disease, Parkinson's Disease
An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease
To evaluate the safety profile of ropinirole XL during long-term treatment in subjects with early and advanced Parkinson's disease
- Trial name
- NCT00632736
- Testing
- Ropinirole XL (formerly CR)
- Where
- 75 sites in United States, Belgium and 7 more
- Volunteers
- 419 people
- Sponsor
- GlaxoSmithKline
Sialorrhoea
A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease
The purpose of this study is to determine whether OC (oxybutynin and clonidine) oral solution is effective in reducing saliva secretion in patients suffering from Parkinson's Disease with excessive salivation.
- Trial name
- NCT01370811
- Testing
- oxybutynin and clonidine oral solution treatment A, oxybutynin and clonidine oral solution treatment B, oxybutynin and clonidine oral solution treatment C
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Orient Pharma Co., Ltd.
Huntington Disease
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm.
- Trial name
- INVEST-HD (NCT07326709)
- Testing
- Votoplam (blinded)
- Where
- 117 sites in United States, Argentina and 25 more
- Volunteers
- 770 people
- Sponsor
- Novartis Pharmaceuticals
Parkinson Disease
Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone
Single-centre, open-label, randomised, two-way crossover study in 28 healthy volunteers. The study consisted of two consecutive single-dose treatment periods separated by a washout period of 14 days or more.
- Trial name
- NCT02305316
- Testing
- BIA 9-1067 non-micronized, BIA 9-1067 micronized
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.